Pain and fatigue are predictors of quality of life in primary Sjögren’s syndrome

Laiza Hombre Dias¹,², Samira Tatiyama Miyamoto³, Raquel Altoé Giovelli³,⁴, Caeër Iamonde Maciel de Magalhães³ and Valeria Valim¹,²,⁶*

Abstract

Background: Few studies have evaluated the relation of quality of life (QoL) with symptoms and disease activity in primary Sjögren’s syndrome (pSS). There is also scant information on the predictors of QoL in this population. The aim of this study was to assess QoL in patients with pSS and to investigate their possible predictors.

Methods: In a cross-sectional study, 77 patients with pSS were evaluated using the following questionnaires: Functional Assessment of Chronic Illness Therapy Fatigue Subscale (FACIT-Fatigue), EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI), EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI), Short Form-36 Health Survey (SF-36) and World Health Organization Quality of Life Assessment (WHOQOL-BREF). Seventy-seven healthy controls responded to the SF-36 and WHOQOL-BREF. The Mann-Whitney test, t-test, Pearson and Spearman correlation, and multiple regression analysis were used in the statistical analysis.

Results: Patients with pSS and healthy controls were matched by gender and age. The mean scores for the ESSDAI, ESSPRI and FACIT-Fatigue were 3.34 ± 4.61, 6.58 ± 2.29 and 26.17 ± 11.02, respectively. Patients had a lower employment rate (36.4% versus 62.3%, \(p < 0.01\)) and higher work disability (10.4% versus 1.3%, \(p < 0.01\)). SF-36 and WHOQOL-BREF values were lower in patients with pSS (\(p < 0.001\)), except in the WHOQOL-BREF environment domain. Pain (ESSPRI), fatigue (FACIT-Fatigue), antinuclear antibody (ANA), anti-Ro-SSA and economic class (Brazilian Economic Classification Criteria - CCEB) were independent predictors of QoL.

Conclusions: The main predictors of poor QoL in patients with pSS were pain and fatigue, and these symptoms had an impact regardless of disease activity, age, schooling, marital status, work disability and fibromyalgia.

Keywords: Sjögren’s syndrome, Quality of life, Pain, Fatigue

Introduction

Primary Sjögren syndrome (pSS) is an autoimmune, chronic and systemic disease that causes an inflammatory lymphocyte infiltrate with dysfunction of the salivary and lacrimal glands, leading to xerostomia and xerophthalmia. Epigenetic mechanisms such as DNA demethylation in epithelial cells and altered expression of microRNAs in salivary glands act on genetically susceptible patients, leading to the production of pathogenic autoantibodies [1]. Primary Sjögren syndrome affects mainly Caucasian women in the 4th to 5th decade of life and presents a broad clinical spectrum, with extraglandular manifestations occurring in more than two-thirds of cases, the most common being arthralgia or arthritis, Raynaud’s phenomenon, skin vasculitis, interstitial pneumonitis and pulmonary fibrosis, peripheral neuropathy, and tubulointerstitial and glomerular nephritis [2–4].

Fatigue, a physical or mental feeling of tiredness, also affects approximately 70% of these patients and is strongly associated with psychosocial factors, occupational dysfunction and a greater number of medical visits but not with sicca severity or laboratory features [5, 6].
In pSS, pain can be explained by different reasons, such as arthritis, pain amplification, and neuropathy. Arthritis is usually symmetrical, predominantly in peripheral and small joints, and may precede or appear simultaneously with sicca symptoms. Small-fiber neuropathy is the most common cause of neuropathic pain and is characterized by distal paraesthesias, alldynia, and burning and itching sensations. Half of the pSS patients present widespread pain, and combined with fatigue and sleep disorders, the diagnosis of associated fibromyalgia may be considered [7].

PSS patients have low quality of life (QoL) in the physical, emotional and social dimensions evaluated by different instruments, such as the Short Form-36 Health Survey (SF-36), the World Health Organization Quality of Life – BREF (WHOQOL-BREF) and the EuroQol 5-dimensions (EQ-5D) [8–20]. There is also an increase in health expenditures, both individual and social, and a higher frequency of work withdrawal in this population. QoL can be influenced by several factors, such as age, schooling and socioeconomic level [6, 9, 11, 12, 21].

Considering the aspects related to the disease itself, pain, fatigue and dryness are associated with worse QoL [11–13, 16, 17, 19, 22]. Comorbidities such as depression, anxiety, and fibromyalgia are also negatively correlated [11, 18]. The association with immunological and biological variables is controversial or weak. Hypergammaglobulinemia, the presence of anti-SSA/Ro, anti-SSB/La antibodies, antinuclear antibody (ANA) or rheumatoid factor (RF), cytopenias, high cytokine levels or RF was performed by the hemagglutination technique, while ANA and RF was performed by indirect immunofluorescence. The association with immunological and biological variables is controversial or weak. Hypergammaglobulinemia, the presence of anti-SSA/Ro, anti-SSB/La antibodies, antinuclear antibody (ANA) or rheumatoid factor (RF), cytopenias, high cytokine levels or RF was performed by the hemagglutination technique, while ANA and RF was performed by indirect immunofluorescence. The association with immunological and biological variables is controversial or weak. Hypergammaglobulinemia, the presence of anti-SSA/Ro, anti-SSB/La antibodies, antinuclear antibody (ANA) or rheumatoid factor (RF), cytopenias, high cytokine levels or RF was performed by the hemagglutination technique, while ANA and RF was performed by indirect immunofluorescence.

Minor salivary gland biopsies were performed and analyzed by rheumatologists and pathologists with experience in pSS and were considered positive when the histopathology showed one or more lymphocytic infiltrates with more than 50 mononuclear cells in an area of 4 mm² [24]. The anti-SSA/Ro and anti-SSB/La laboratory tests were performed by the hemagglutination technique, while ANA was performed by indirect immunofluorescence and RF by the latex test. The SF-36 and WHOQOL-BREF questionnaires were used to assess QoL in pSS patients and healthy controls.

To evaluate the activity of the disease, two physicians experienced in pSS applied the ESSDAI. It has 12 domains of systemic evaluation (constitutional, lymphadenopathy, glandular, articular, cutaneous, respiratory, renal, muscular, peripheral and central nervous system, hematological and biological). The domains have different weights in the final score, 0 to 123, according to the level of activity [27, 28]. Values lower than 5 are considered to indicate low disease activity; values from 5 to 13, moderate activity; and values greater than or equal to 14, high activity [29].

Symptoms and QoL were assessed using self-administered questionnaires, and a trained professional was available to assist participants when needed. PSS patients answered the ESSPRI, which measures three symptoms related to the disease: dryness, pain and fatigue. Each domain ranges from 0 to 10, and the result is the average of the three domains [30]. Values less than 5 are considered acceptable [29].

Fatigue in pSS patients was evaluated through the Functional Assessment of Chronic Illness Therapy - fatigue (FACIT-fatigue). The FACIT system originally developed to evaluate QoL in cancer patients has been widely used in several chronic diseases. Its score ranges from 0 to 52, and its value is inversely proportional to the degree of fatigue [31]. The SF-36 and WHOQOL-BREF questionnaires were used to assess QoL in pSS patients and healthy controls. The SF-36 is an easy-to-administer instrument.
consisting of 36 items divided into 8 domains: physical functioning, physical role functioning, bodily pain, general health, vitality, social functioning, emotional role functioning and mental health. These can be grouped into two components that summarize the dimensions: physical (PCS) and mental (MCS) component summaries. Its final score ranges from 0 to 100, and the higher the score, the better the overall health condition [32]. Developed by the World Health Organization (WHO), the WHOQOL-BREF is an abbreviated version of the WHOQOL-100. It is composed of 26 questions. The first two questions are general QoL issues, and the remaining 24 facets will form four domains: physical, psychological, social relations and environment. The total score ranges from zero to 100, and the higher its value, the better the QoL [33, 34].

The chi-square, Fisher and likelihood ratio association tests were used for qualitative variables among patients with pSS and healthy controls. The Kolmogorov-Smirnov test was used to evaluate the normal distribution of the data. For quantitative variables, the Mann-Whitney test was used when there was a breakdown of normality, and with normal data, the t test was used. Pearson or Spearman tests were used in the correlations. To identify independent predictors for quality of life, stepwise linear regression analysis was performed. The variables considered in the analysis were age, weight, body mass index (BMI), smoking, alcoholism, marital status, schooling, fibromyalgia, CCEB, work disability (sick leave or early retirement), ESSDAI, ESSPRI, FACIT-Fatigue, salivary gland biopsy, ANA, anti-SSA/Ro, anti-SSB/La and RF. Variables with a statistical significance level of 10% were included in the multiple regression analysis. Statistical significance was set at a p value of ≤0.05. The Statistical Package for the Social Sciences (SPSS), version 20.0, Armonk, New York (NY), 2011 software was used.

**Results**

Of 127 pSS outpatients, 27 were excluded because they did not meet the AECG, and 33 were not willing to participate.

Seventy-seven pSS patients and 77 healthy women were included, aged 27 to 67 years. Groups were similar in age, ethnicity, schooling, marital status and economic classification. Patients had a lower employment rate (36.4% versus 62.3%, p < 0.01) and higher work disability (10.4% versus 1.3%, p < 0.01). Moreover, the patients had a low disease activity (ESSDAI 3.34 ± 4.61) and a low frequency of autoantibodies, characterizing a sample with mild disease. Biological and articular domains were the most frequently affected. In contrast, the patients presented a high level of symptoms (ESSPRI 6.58 ± 2.29). Among patients with pSS, the percentage of fibromyalgia was 42.9% (Table 1).

| Table 1 Demographic and clinical data in pSS patients and healthy controls |
|-----------------------------|-----------------------------|
|                             | pSS (n = 77) | Controls (n = 77) |
| Age, mean, years            | 52.34 (9.03) | 52.27 (8.91) |
| Ethnicity                   |               |                 |
| Black (%)                   | 11.7          | 13              |
| Brown (%)                   | 59.7          | 49.4            |
| White (%)                   | 24.7          | 37.7            |
| Indigenous (%)              | 2.6           | 0               |
| Education                   |               |                 |
| < 8 years (%)               | 50.7          | 57.2            |
| ≥ 8 years (%)               | 48.1          | 40.3            |
| Never studied (%)           | 1.2           | 2.5             |
| Marital status              |               |                 |
| Married (%)                 | 66.2          | 63.6            |
| Not married (%)             | 14.3          | 13              |
| Divorced/widow (%)          | 19.5          | 23.4            |
| CCEB                        |               |                 |
| A (%)                       | 1.3           | 0               |
| B (%)                       | 23.4          | 26.6            |
| C (%)                       | 52            | 49.3            |
| D (%)                       | 18.2          | 24              |
| E (%)                       | 0             | 0               |
| *Employment rate (%)        | 36.4          | 62.3            |
| Work disability (%)*        | 10.4          | 1.3             |
| Positive salivary biopsy (focus score ≥ 1) (%) | 90.5 | |
| Anti-SSA/Ro (%)             | 33.3          |                 |
| Anti-SSB/La (%)             | 24            |                 |
| Antinuclear antibody (%)    | 68.9          |                 |
| Rheumatoid factor (%)       | 29.2          |                 |
| Fibromyalgia (%)            | 42.9          |                 |
| FACIT-Fatigue, mean, SD     | 26.17 (11.02) |                 |
| ESSPRI, mean, SD            | 6.58 (2.29)   |                 |
| Fatigue, mean, SD           | 6.38 (2.57)   |                 |
| Dryness, mean, SD           | 6.53 (2.78)   |                 |
| Pain, mean, SD              | 6.84 (3.12)   |                 |
| Extra glandular manifestations (%) | 49.4 | |
| ESSDAI, mean SD             | 3.34 (4.61)   |                 |

*p < 0.05

Table 1: Demographic and clinical data in pSS patients and healthy controls

The QoL measured by SF-36 and WHOQOL-BREF was worse in patients with pSS than in healthy controls, except for the environment domain tested by WHOQOL-BREF, which was similar for both groups (Table 2).
In the pSS group, patients with a nonacceptable ESSPRI (≥ 5) had all WHOQOL-BREF and most SF-36 domains worse than patients with an acceptable ESSPRI (Table 3). Patients with pSS and fibromyalgia had worse QoL values in bodily pain (SF-36) and physical health (WHOQOL-BREF) (Table 4).

There was a moderate-to-strong correlation of FACIT-Fatigue with all domains of QoL questionnaires. The ESSPRI also correlated with all QoL domains. The ESS-DAI showed only a weak correlation with the emotional role functioning domain of the SF-36 and did not correlate with fatigue indexes (FACIT-Fatigue) and ESSPRI (Table 5).

In the regression analysis, pain (ESSPRI), fatigue (FACIT-Fatigue), antinuclear antibody (ANA), anti-Ro-SSA and economic class (Brazilian Economic Classification Criteria - CCEB) were independent predictors of QoL. The symptoms measured by FACIT-Fatigue and ESSPRI pain were the main predictors of poor QoL, regardless of age, marital status, schooling, work disability, disease activity and fibromyalgia. In the PCS of the SF-36, the predictors for the worst values were pain, fatigue, and the presence of ANA and anti-SSA/Ro autoantibodies. Fatigue was the only predictor in the MCS of the SF-36 and psychological health domain of the WHOQOL-BREF. Pain interfered with the PCS of the SF-36, physical health, social relations and environmental domains of the WHOQOL-BREF (Table 6).

### Table 2 Comparison of quality of life between pSS patients and healthy controls

|SF-36| pSS (n = 77) | Controls (n = 77) |
|---|---|---|
|Physical functioning| 37.3 ± 24.2| 80.5 ± 20.8 |
|Physical role functioning| 27.6 ± 35.9| 73.4 ± 37.2 |
|Bodily pain| 36.7 ± 22.2| 69.5 ± 21.4 |
|General health| 43.2 ± 17.9| 69.5 ± 20.0 |
|Vitality| 37.2 ± 20.6| 64.8 ± 20.9 |
|Social functioning| 48.3 ± 26.9| 74.8 ± 23.1 |
|Emotional role functioning| 31.1 ± 38.6| 69.3 ± 40.0 |
|Mental health| 46.2 ± 22.3| 67.8 ± 23.0 |
|PCS| 33.1 ± 9.1| 48.9 ± 8.5 |
|MCS| 37.2 ± 11.4| 46.8 ± 12.3 |

WHOQOL-BREF

||| |
|---|---|---|
|Physical health| 41.6 ± 16.8| 67.7 ± 16.8 |
|Psychological health| 53.4 ± 18.8| 63.9 ± 15.9 |
|Social relations| 55.5 ± 22.0| 65.4 ± 18.2 |
|Environment| 49.1 ± 12.7| 53.0 ± 16.5 |

SF-36 Short Form 36 Health Survey, pSS primary Sjögren’s Syndrome, PSC Physical Component Summary, MCS Mental Component Summary, WHOQOL-BREF World Health Organization Quality of Life Assessment

*p < 0.01

### Table 3 Comparison of quality of life between patients with acceptable and non-acceptable ESSPRI

|SF36| Acceptable| Non-acceptable |
|---|---|---|
|Physical functioning| 63.44 ± 29.08| 30.83 ± 17.54 |
|Physical role functioning| 35.94 ± 43.75| 25.00 ± 33.19 |
|Bodily pain| 55.06 ± 25.69| 31.80 ± 18.56 |
|General health| 53.75 ± 19.21| 40.57 ± 16.66 |
|Vitality| 47.19 ± 34.92| 34.92 ± 18.31 |
|Social functioning| 54.66 ± 47.02| 47.02 ± 27.27 |
|Emotional role functioning| 52.08 ± 25.00| 43.87 ± 21.05 |
|Mental health| 56.00 ± 24.57| 43.87 ± 21.05 |
|PCS| 40.21 ± 10.88| 31.28 ± 7.62 |
|MCS| 40.83 ± 13.14| 36.31 ± 10.84 |

WHOQOL-BREF

|| Acceptable| Non-acceptable |
|---|---|---|
|Physical health| 56.70 ± 19.25| 37.54 ± 13.76 |
|Psychological health| 63.02 ± 16.66| 50.90 ± 18.75 |
|Social relations| 71.35 ± 14.58| 51.11 ± 21.94 |
|Environment| 54.88 ± 9.20| 47.53 ± 13.23 |

ESSPRI EULAR Sjögren’s syndrome patient reported index, SF-36 Short Form-36 Health Survey, PCS Physical Component Summary, MCS Mental Component Summary, WHOQOL-BREF World Health Organization quality of life – BREF

*p < 0.01; **p < 0.05

### Table 4 Comparison of QoL between pSS patients with fibromyalgia

| | Fibromyalgia | No |
|---|---|---|
|SF-36| Physical functioning| 30.9 ± 18.9| 42.6 ± 26.5 |
| | Physical role functioning| 22.0 ± 30.5| 32.4 ± 39.1 |
| | Bodily pain| 25 ± 15.3| 45.6 ± 22.4 |
| | General health| 37.9 ± 17.2| 47.4 ± 17.4 |
| | Vitality| 30.9 ± 17.4| 42.2 ± 21.4 |
| | Social functioning| 42.3 ± 25.2| 53.7 ± 27.7 |
| | Emotional role functioning| 28.3 ± 38.3| 34.1 ± 39.0 |
| | Mental health| 41.7 ± 22.7| 49.6 ± 21.4 |
| | PCS| 29.7 ± 6.5| 35.8 ± 9.8 |
| | MCS| 35.7 ± 11.6| 38.6 ± 11.1 |

WHOQOL-BREF

| | Acceptable| Non-acceptable |
|---|---|---|
|Physical health| 35.5 ± 15.3| 46.2 ± 16.5 |
|Social relations| 51.0 ± 23.0| 58.9 ± 20.9 |
|Environment| 45.6 ± 11.4| 51.8 ± 13.1 |
|Psychological health| 48.7 ± 19.3| 56.8 ± 17.8 |

QoL Quality of Life, pSS primary Sjögren’s Syndrome, SF-36 Short Form 36 Health Survey, PCS Physical Component Summary, MCS Mental Component Summary, WHOQOL-BREF World Health Organization Quality of Life Assessment

*p < 0.01
Table 5 Correlation of quality of life, disease activity, symptoms and fatigue

| SF36         | ESSDAI | ESSPRI dryness | ESSPRI fatigue | ESSPRI pain | ESSPRI Total | FACIT-Fatigue |
|--------------|--------|---------------|----------------|-------------|--------------|---------------|
| Physical functioning | 0.04   | −0.44**       | −0.29**        | −0.55**     | −0.56**      | 0.53**        |
| Physical role functioning | 0.01   | −0.17         | −0.08          | −0.23*      | −0.24*       | 0.35**        |
| Bodily pain  | 0.03   | −0.33**       | −0.23*         | −0.59**     | −0.53**      | 0.56**        |
| General health | −0.08  | −0.27*        | −0.17          | −0.34**     | −0.34**      | 0.56**        |
| Vitality     | −0.04  | −0.23*        | −0.26*         | −0.36**     | −0.39**      | 0.56**        |
| Social functioning | −0.01  | −0.33**       | −0.18          | −0.21       | −0.29*       | 0.45**        |
| Emotional role functioning | −0.24** | −0.31** | −0.11          | −0.23       | −0.29*       | 0.48**        |
| Mental health | 0.04   | −0.21         | −0.23*         | −0.31**     | −0.28*       | 0.46**        |
| PCS          | 0.06   | −0.35**       | −0.21          | −0.53**     | −0.5**       | 0.46**        |
| MCS          | −0.14  | −0.2          | −0.17          | −0.12       | −0.24*       | 0.48**        |

WHOQOL Bref

| Physical health | −0.09 | −0.34**       | −0.19          | −0.43**     | −0.50**      | 0.68**        |
| Psychological health | −0.08 | −0.32**       | −0.19          | −0.36**     | −0.38**      | 0.56**        |
| Social relations | −0.03 | −0.17         | −0.2           | −0.34**     | −0.33**      | 0.37**        |
| Environment     | −0.01 | −0.19         | −0.18          | −0.49**     | −0.34**      | 0.32**        |
| ESSDAI         | −0.11 | −0.01         | −0.04          | −0.08       | −0.06        |               |

ESSDAI: EULAR Sjögren’s syndrome disease activity index, ESSPRI: EULAR Sjögren’s syndrome patient reported index, FACIT: Fatigue – Functional Assessment of Chronic Illness Therapy-Fatigue, SF-36: Short Form-36 Health Survey, PCS: Physical Component Summary, MCS: Mental Component Summary, WHOQOL-BREF: World Health Organization quality of life – BREF

*p < 0.01; **p < 0.05

Discussion

Here, PSS patients were found to have lower QoL scores than healthy controls, corroborating previous studies in other countries [11–13, 15–19, 22]. The relevance of the present data was to demonstrate that symptoms, but not disease activity, were the main predictors of low QoL.

Few studies have performed multivariate analyses to identify predictors of QoL in pSS. Cornec et al. corroborated the results of our study, showing that disease activity is not associated with greater QoL impairments in 120 French patients with moderate-to-high levels of systemic activity, despite the low level of disease activity in our patients [35]. Disease activity (ESSDAI) was also not a predictor of QoL in 639 pSS patients from United Kingdom (UK) [18] and in 104 Korean patients [17]. In contrast, Omma et al. found that the ESSDAI was an independent determinant of all SF-36 domains, with the exception of the vitality domain, in 105 patients from Turkey, most of whom had low to moderate levels of disease activity [36]. As in Liu et al.’s study [37], our results showed that pain and fatigue were independently associated with a low physical component summary (PCS) of the SF-36 and that fatigue was associated with a low mental component summary (MCS) of the SF-36. In the Cornec et al. study, only pain was associated [35]. Omma et al. demonstrated that the ESSPRI was an independent determinant of bodily pain, general health, mental health and PCS of the SF-36, while fatigue was

Table 6 Predictors of quality of life

| SF-36       | WHOQOL-BREF          |
|-------------|----------------------|
|             | PCS: 0.56            |
|             | MCS: 0.22            |
|             | Physical health: 0.52|
|             | Psychological health: 0.36|
|             | Social relations: 0.23|
|             | Environment: 0.30    |

| Predictor       | β (p-value) | β (p-value) | β (p-value) | β (p-value) | β (p-value) |
|-----------------|-------------|-------------|-------------|-------------|-------------|
| ESSPRI-pain     | −1.16       | 0.00        | −1.48       | 0.00        | −1.53       | 0.06        |
| FACIT-Fatigue   | 0.31        | 0.00        | 0.51        | 0.00        | 0.88        | 0.00        |
| ANA             | −4.64       | 0.01        | 0.88        | 0.00        | 1.00        | 0.00        |
| Anti-SSA/Ro     | −4.09       | 0.01        | 0.88        | 0.00        | 1.00        | 0.00        |
| CCEB            | −4.91       | 0.05        | −1.63       | 0.00        | −1.63       | 0.00        |

SF-36: Short Form-36 Health Survey, WHOQOL-BREF: World Health Organization quality of life – BREF, PCS: Physical Component Summary, MCS: Mental Component Summary, ANA: Antinuclear Antibody, CCEB: Brazilian Economic Classification Criteria
Results showed a correlation between the ESSDAI only and the emotional aspects domain of the SF-36, and yet this correlation was weak, not being confirmed as a predictor of QoL in patients with pSS. Sharing a similar result, a cohort in the UK using the EQ-5D to assess QoL demonstrated a weak correlation with the ESSDAI [19]. Yacoub et al. used the degree of activity in salivary gland biopsy, immunological status and severity of systemic involvement as a way of assessing disease activity, and they found no correlation with QoL or fatigue [13]. It is not clear why there is a weak association between disease activity (ESSDAI) and QoL. One possible answer could be the wide range of ESSDAI scores (0–123) in samples with low mean activity. In addition, ESSDAI is an index that does not assess established damage, only current activity; thus, perhaps the patient’s perception about the QoL is not modified at that moment, but when there is an established organic dysfunction. Other studies correlating injury rates with disease activity and QoL could better elucidate the issue.

QoL was worse in patients with higher nonacceptable ESSPRI, and it was not associated with ESSDAI, corroborating that symptoms (fatigue, pain and dryness) impact QoL more than disease activity.

In pSS, QoL has been found to be associated with fatigue, pain/articular involvement, ocular and oral involvement, pruritus, sexual dysfunction, impaired sleep, pulmonary manifestations, psychological dysfunction and impaired physical function [20]. On the other hand, delayed diagnosis, protracted course of the disease, and the lack of social support are also causes of the decline in the quality of life in these patients [37].

Fatigue is considered a hallmark of pSS [5]. In the present study, fatigue (FACIT-fatigue) was strongly associated with all dimensions of QoL and was an independent risk factor for the physical and mental aspects of QoL in both instruments, SF-36 and WHOQOL-BREF. In contrast, there was no association between fatigue and disease activity measured by the ESSDAI. Taken together, the results suggest that fatigue is itself associated with pSS but may not be explained by disease activity.

Recent evidence has shown weak or no association with inflammatory biomarkers such as interleukin (IL)-1β, IL-2, IL-6, IL-10 and tumor necrosis factor alpha (TNF-α). In the same direction, immunosuppressors and biological therapy failed to treat fatigue in pSS [38]. However, Howard et al. showed that lower levels of the pro-inflammatory cytokines inducible protein (IP)-10 and interferon-gamma (IFN-γ), together with pain and depression, were the most important predictors of fatigue [39], and Davies et al. demonstrated that TNF-α and LT-α have an inverse relationship with fatigue severity in pSS [40]. A proteomic study of cerebrospinal fluid showed that some proteins that are increased in pSS have a role in the downregulation of inflammation and in the cellular stress defense (hemopexin, pigment epithelium-derived factor, clusterin, osteopontin, and selenium-binding protein 1). These results suggest that some fatigue signaling pathways are associated with “cellular protection and defense” and are not directly related to proinflammatory factors [41]. Nonetheless, the evidence for an association between fatigue and disease activity – or any other inflammatory markers – remains controversial.

In fact, the pathogenesis of fatigue in pSS is unknown but seems to be associated with a lower aerobic capacity and lower physical activity levels, sleep disturbances, autonomic dysfunction, depression, psychological profiles, and fibromyalgia [38]. It is noteworthy that, in the multiple regression models, fatigue measured by FACIT-Fatigue was the only predictor of the MCS of SF-36 and the psychological component of WHOQOL-BREF. These data indicate that this symptom impacts not only the physical aspects but also the mental health of these individuals. Other studies have pointed to depression as an important determinant of poor QoL along with fatigue in these patients [11, 17, 18], which could partially explain the low values of the determination coefficients in the mental domain of the SF-36, as well as in the psychological, social relations and environmental domains of the WHOQOL-BREF. However, we did not evaluate psychiatric disorders, such as depression or anxiety, which is a limitation of this study. Interestingly, aerobic exercise has been found to improve fatigue, but not QoL and depression [42], and resistance exercise has been found to improve QoL [43]. Clearly, many efforts still need to be made to elucidate the pathogenesis of fatigue, as well as to identify pharmacological and nonpharmacological therapies to treat fatigue and improve the QoL in pSS.

Pain was a determinant for lower QoL in the physical, social relations and environmental domains but not for mental aspects. A large proportion of patients with pSS have noninflammatory musculoskeletal pain without the laboratory or clinical abnormalities of arthritis. Among patients with pSS, cases of pain amplification syndrome are associated with a benign pole of the disease, with a low frequency of autoantibodies and extraglandular manifestations [44].

The prevalence of fibromyalgia in pSS varies from 12 to 55% [7]. In our study, the prevalence was 42.9%. This large range can certainly be explained by the various criteria to diagnose fibromyalgia as well as pSS that have been applied over time. Indeed, pain and fatigue are common symptoms in both fibromyalgia and pSS, and the association of the two can be a misleading factor.
However, in the present study, fatigue and pain were the main predictors of poor QoL, regardless of the diagnosis of fibromyalgia, indicating that pSS itself was associated with poor QoL. Lendrem et al. found no difference in QoL between those with fibromyalgic symptoms and those without [18]. Notwithstanding, our study did not investigate other factors, such as subclinical autonomic dysfunction and sleep disorders, that could contribute to pain and fatigue in these patients with pSS without fibromyalgia [45].

The present study demonstrated a contribution of ANA and Anti-Ro/SSA, even if discrete, to worse values in the SF-36 physical domain. This information differs from the findings of other studies in which no correlation was found between antibodies and QoL [9, 13, 18]. However, it is well established in the literature that patients with positive autoantibodies evolve to greater glandular dysfunction and systemic manifestations [46, 47].

Although dryness is the main symptom and causes great discomfort in pSS patients, it was not a predictor of QoL, as demonstrated in previous studies [11, 35]. A review on QoL in pSS mentioned that it is possible this may reflect an inadequacy of single VAS scales, as is often used in such studies, to capture the breadth and impact of oral and ocular involvement. That review also showed that non-SS sicca syndrome patients have an impairment of QoL similar to that observed in pSS and other chronic diseases such as rheumatoid arthritis, systemic lupus erythematosus and fibromyalgia [20].

In the comparison between patients and healthy controls, SF-36 and WHOQOL-BREF domains were worse in patients with pSS, showing that the disease had a negative influence on the different aspects of QoL. Interestingly, the environmental domain, which is associated with transportation-related and residential conditions, in pSS was similar to that in healthy controls, probably because both groups showed similar socioeconomic levels.

Other relevant information included the lower number of employed individuals and the greater amount of sick leave among pSS patients compared to healthy controls. Patients with pSS also generate a higher cost to the health system, since they use more medical services, have higher hospitalization rates and use more medications [11, 20]. These data demonstrate how much the disease interferes not only emotionally and physically but also socially and individually, affecting employers and the government, increasing social security costs and reducing the life expectancy of the worker.

The study has limitations. Medications used by patients and other comorbidities were not collected. These data could have enriched the analysis, as some medications can yield adverse effects and other diseases may have symptoms with negative impacts on QoL. Questionnaires about emotional aspects such as depression and anxiety were also not applied, and these data could have improved the values of the mental domain determination coefficients.

Conclusion
This study demonstrated that the main predictors of poor QoL in patients with pSS were pain and fatigue, independent of disease activity, age, schooling, work disability, marital status and fibromyalgia.

Abbreviations
ANA: Antinuclear antibody; BMI: Body mass index; CCEB: Brazilian Economic Classification Criteria; ESSDAI: EULAR Sjögren’s Syndrome Disease Activity Index; ESSPRI: EULAR Sjögren’s Syndrome Patient Reported Index; FACIT: Fatigue: Functional Assessment of Chronic Illness Therapy Fatigue Subscale; pSS: Primary Sjögren’s syndrome; QoL: Quality of life; RF: Rheumatoid factor; SF-36: Short Form-36 Health Survey; WHOQOL-BREF: World Health Organization Quality of Life Assessment

Acknowledgements
Not applicable.

Authors’ contributions
All authors contributed to the conception and design of the study, analysis and interpretation of the data. In addition, all authors performed a critical review and read and approved the final version of this manuscript.

Funding
Not applicable.

Availability of data and materials
The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Clinical Medicine, Cassiano Antonio Moraes University Hospital / EBSERH, Federal University of Espírito Santo (Ufes), Av. Marechal Campos, 1468, Maruípe, Vitória, ES CEP: 29075-910, Brazil. 2Brazilian Society of Rheumatology, São Paulo, Brazil. 3Department of Integrated Health Education, Federal University of Espírito Santo (Ufes), Av. Marechal Campos, 1468, Maruípe, Vitória, ES CEP: 29075-910, Brazil. 4Department of Clinical Medicine, School of Sciences of Santa Casa de Misericórdia de Vitória (Emescam), Av. Nossa Senhora da Penha 2190, Vitória, ES 29045-925, Brazil. 5Federal University of Espírito Santo (Ufes), Av. Marechal Campos, 1468, Maruípe, Vitória, ES CEP: 29075-910, Brazil. 6Brazilian Sjögren Syndrome Commission, São Paulo, Brazil.
Received: 6 March 2020 Accepted: 27 April 2021
Published online: 29 May 2021

References

1. Cafaro G, et al. One year in review 2019: Sjögren’s syndrome. Clin Exp Rheumatol. 2020;38(1 Suppl):1183(3–15).
2. Patel R, Shahane A. The epidemiology of Sjögren’s syndrome. Clin Epidemiol. 2014;6:47–55.
3. Ramos-Casals M, Solani R, Rosas J, Camps MT, Gil A, del Pino-Montes J, et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore). 2008;87(4):210–9. https://doi.org/10.1097/MD.0b013e31816ef93c.
4. Lendrem D, Mitchell S, McMeekin P, Gompels L, Hackett K, Bowman S, et al. Do the EULAR Sjögren’s syndrome outcome measures correlate with health status in primary Sjögren’s syndrome? Rheumatology (Oxford). 2015;54(4):655–9. https://doi.org/10.1093/rheumatology/keu361.
5. Miyamoto ST, Valim V, Fisher BA. Health-related quality of life and costs in Sjögren’s syndrome. Rheumatology. 2019. https://doi.org/10.1093/rheuma
tology/key570.
6. Gaghany R, Prahu A, Allan RB, Clarke AE, Sutcliffe N, Pierre YS, et al. Direct healthcare costs and predictors of costs in patients with primary Sjögren’s syndrome. Rheumatology (Oxford). 2007;46(1):105–11. https://doi.org/10.1093/rheumatology/kel155.
7. Kannel UV, Maddison BA, Whitaker R. Impact of primary Sjögren’s syndrome on smell and taste: effect on quality of life. Rheumatology (Oxford). 2009;48(12):1512–4. https://doi.org/10.1093/rheumatology/kep249.
8. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554–8. https://doi.org/10.1136/ard.61.6.554.
9. Associação Brasileira de Empresas de Pesquisa. Critério de Classificação econômica Brasil. São Paulo: Associação Brasileira de Empresas de Pesquisa; 2012. p. 4.
10. Wolfe F, et al. The American College of Rheumatology 1990 Criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33(2):160–72.
11. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62(5):600–10. https://doi.org/10.1002/acr.20140.
12. Seror R, Ravaud P, Bowman SJ, Baron G, Tsoufas A, Theander H, et al. EULAR Sjögren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren’s syndrome. Ann Rheum Dis. 2010;69(6):1103–9. https://doi.org/10.1136/ard.2009.116019.
13. Serrano EV, Valim V, Miyamoto ST, Grovelli RA, Pagannotti MA, Cadé NV. Transcultural adaptation of the “EULAR Sjögren’s syndrome disease activity index (ESSDAI)” into Brazilian Portuguese. Rev Bras Reumatol. 2013;53(6):483–93. https://doi.org/10.1590/1678-9990.2013.40003.
14. Seror R, Bootma H, Sarau A, Bowman SJ, Theander E, Brun JG, et al. Defining disease activity states and clinically meaningful improvement in primary Sjögren’s syndrome with EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis. 2016;75(2):382–6. https://doi.org/10.1136/annrheumdis-2014-200038.
15. Seror R, Ravaud P, Mariette X, Bootma H, Theander E, Hansen A, et al. EULAR Sjögren’s syndrome patient reported index (ESSPRI): development of a consensus patient index for primary Sjögren’s syndrome. Ann Rheum Dis. 2011;70(6):968–72. https://doi.org/10.1136/ard.2011.143743.
16. Cella D, Yount S, Sorenson M, Chartash E, Sengupta N, Grober J. Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005;32(5):811–9.
17. Ciconelli RM, et al. Brazilian-Portuguese version of the SF-36. A reliable and valid quality of life outcome measure. Rev Bras Reumatol. 1999;39(3):143–50.
18. World Health Organization (WHO). WHOOQL-BREF: Introduction, administration, scoring and generic version of the assessment. Geneva: WHOQOL Group; 1996.
19. Fleck MP, Louzada S, Xavier M, Chachamovich E, Veira G, Santos L, et al. Application of the Portuguese version of the abbreviated instrument of quality life WHOQOL-BREF. Rev Saude Publica. 2000;34(2):178–83. https://doi.org/10.1590/S0080-62352000000300012.
20. Cornec D, Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdregor A, et al. Severe health-related quality of life, fatigue, anxiety and depression in primary Sjögren’s syndrome? Arch Med Sci. 2018;14(4):830–7. https://doi.org/10.5114/ams.2017.70300.
21. Liu Z, Dong Z, Liang X, Liu J, Xuan L, Wang J, et al. Health-related quality of life and psychological status of women with primary Sjögren’s syndrome: a cross-sectional study of 304 Chinese patients. Medicine (Baltimore). 2017; 96(50):e9208. https://doi.org/10.1097/MD.0000000000009208.
38. Miyamoto ST, Lendrem DW, Ng WF, Hackett KL, Valim V. Managing fatigue in patients with primary Sjögren’s syndrome: challenges and solutions. Open Access Rheumatol. 2019;11:77–88. https://doi.org/10.2147/OARRR.S16790.

39. Howard Tripp N, Tarn J, Natasari A, Gillespie C, Mitchell S, Hackett KL, et al. Fatigue in primary Sjögren’s syndrome is associated with lower levels of proinflammatory cytokines. RMD Open. 2016;2(2):e000282. https://doi.org/10.1136/rmdopen-2016-000282.

40. Davies K, et al. Fatigue in primary Sjögren’s syndrome (pSS) is associated with lower levels of proinflammatory cytokines: a validation study. Rheumatol Int. 2019;39(11):1867–73. https://doi.org/10.1007/s00296-019-04354-0.

41. Larssen E, et al. Fatigue in primary Sjögren’s syndrome: a proteomic pilot study of cerebrospinal fluid. SAGE Open Med. 2019;7:2050312119850390.

42. Miyamoto ST, Valim V, Carletti L, Ng WF, Perez AJ, Lendrem DW, et al. Supervised walking improves cardiorespiratory fitness, exercise tolerance, and fatigue in women with primary Sjögren’s syndrome: a randomized-controlled trial. Rheumatol Int. 2019;39(2):227–38. https://doi.org/10.1007/s00296-018-4213-z.

43. Minali PA, Pimentel CFMG, de Mello MT, Lima GHO, Dardin LP, Garcia ABA, et al. Effectiveness of resistance exercise in functional fitness in women with primary Sjögren’s syndrome: randomized clinical trial. Scand J Rheumatol. 2020;59(1):47–56. https://doi.org/10.1080/03009742.2019.1602880.

44. ter Borg EJ, Kelder JC. Lower prevalence of extra-glandular manifestations and anti-SSB antibodies in patients with primary Sjögren’s syndrome and widespread pain: evidence for a relatively benign subset. Clin Exp Rheumatol. 2014;32(3):349–53.

45. Giles I, Isenberg D. Fatigue in primary Sjögren’s syndrome: is there a link with the fibromyalgia syndrome? Ann Rheum Dis. 2000;59(11):875–8. https://doi.org/10.1136/ard.59.11.875.

46. Matulinska M, et al. Sjögren’s syndrome: still not fully understood disease. Rheumatol Int. 2015;35(2):233–41. https://doi.org/10.1007/s00296-014-3072-5.

47. Theander E, Andersson SI, Manthorpe R, Jacobsson LT. Proposed core set of outcome measures in patients with primary Sjögren’s syndrome: 5 year follow up. J Rheumatol. 2005;32(8):1495–502.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.